Concepedia

Author

Sara Cortés-Lara

Health Research Institute of the Balearic Islands

Also Known As

Sara Cortes-Lara, Sara Cortés-Lara

17

Publications

556

Citations

10

H-Index

19

Concepts

All Affiliations

Health Research Institute of the Balearic IslandsHospital Universitario Son EspasesInstituto de Investigación Biomédica de A CoruñaUniversity of CórdobaInstituto Maimónides de Investigación Biomédica de Córdoba
SC

About

Sara Cortés-Lara is an author at Health Research Institute of the Balearic Islands specializing in medicine, microbiology, and clinical microbiology.

Top Concepts

#ConceptH-IndexPublicationsCitations

1

Medicine

3

3

117

2

Microbiology

3

3

117

3

Health Sciences

1

1

12

4

Biology

1

1

27

5

Antibiotics

1

1

12

Sara Cortés-Lara

×

10

Publications

537

Citations

10

H-Index

YearCitations

Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology

Ester del Barrio-Tofiño, Laura Zamorano, Sara Cortés-Lara,

Journal of Antimicrobial Chemotherapy

2019

144

Susceptibility profiles and resistance genomics of <i>Pseudomonas aeruginosa</i> isolates from European ICUs participating in the ASPIRE-ICU trial

Gabriel Torrens, Thomas van der Schalk, Sara Cortés-Lara,

Journal of Antimicrobial Chemotherapy

2022

81

Activity of Imipenem-Relebactam against a Large Collection of Pseudomonas aeruginosa Clinical Isolates and Isogenic β-Lactam-Resistant Mutants

Pablo A. Fraile-Ribot, Laura Zamorano, Rocío Orellana,

Antimicrobial Agents and Chemotherapy

2019

80

Predicting Pseudomonas aeruginosa susceptibility phenotypes from whole genome sequence resistome analysis

Sara Cortés-Lara, Ester del Barrio-Tofiño, Carla López-Causapé,

Clinical Microbiology and Infection

2021

78

Emergence of Resistance to Novel Cephalosporin–β-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump

María A. Gomis-Font, Cristina Pitart, Ester del Barrio-Tofiño,

Antimicrobial Agents and Chemotherapy

2021

49

<i>In vitro</i>evolution of cefepime/zidebactam (WCK 5222) resistance in<i>Pseudomonas aeruginosa</i>: dynamics, mechanisms, fitness trade-off and impact on<i>in vivo</i>efficacy

Isabel M. Barceló, Gabriel Cabot, Snehal Palwe,

Journal of Antimicrobial Chemotherapy

2021

29

Association between Pseudomonas aeruginosa O-antigen serotypes, resistance profiles and high-risk clones: results from a Spanish nationwide survey

Ester del Barrio-Tofiño, Irina Sánchez-Diener, Laura Zamorano,

Journal of Antimicrobial Chemotherapy

2019

27

Prokaryotic microbiota in the digestive cavity of the jellyfish Cotylorhiza tuberculata

Sara Cortés-Lara, Mercedes Urdiain, Merit del Rocío Mora-Ruiz,

Systematic and Applied Microbiology

2015

27

Ceftolozane/tazobactam plus tobramycin against free-floating and biofilm bacteria of hypermutable Pseudomonas aeruginosa epidemic strains: Resistance mechanisms and synergistic activity

Akosua Adom Agyeman, Carla López-Causapé, Kate E. Rogers,

International Journal of Antimicrobial Agents

2023

12

Ceftolozane-Tazobactam against Pseudomonas aeruginosa Cystic Fibrosis Clinical Isolates in the Hollow-Fiber Infection Model: Challenges Imposed by Hypermutability and Heteroresistance

Jessica R. Tait, Marina Harper, Sara Cortés-Lara,

Antimicrobial Agents and Chemotherapy

2023

10

Page 1